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Abstract
The recent development of the Sleeping Beauty (SB) system has led to the development of novel mouse models of cancer.
Unlike spontaneous models, SB causes cancer through the action of mutagenic transposons that are mobilized in the
genomes of somatic cells to induce mutations in cancer genes. While previous methods have successfully identified many
transposon-tagged mutations in SB-induced tumors, limitations in DNA sequencing technology have prevented a
comprehensive analysis of large tumor cohorts. Here we describe a novel method for producing genetic profiles of SB-
induced tumors using Illumina sequencing. This method has dramatically increased the number of transposon-induced
mutations identified in each tumor sample to reveal a level of genetic complexity much greater than previously appreciated.
In addition, Illumina sequencing has allowed us to more precisely determine the depth of sequencing required to obtain a
reproducible signature of transposon-induced mutations within tumor samples. The use of Illumina sequencing to
characterize SB-induced tumors should significantly reduce sampling error that undoubtedly occurs using previous
sequencing methods. As a consequence, the improved accuracy and precision provided by this method will allow candidate
cancer genes to be identified with greater confidence. Overall, this method will facilitate ongoing efforts to decipher the
genetic complexity of the human cancer genome by providing more accurate comparative information from Sleeping
Beauty models of cancer.
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Introduction
Recent work has indicated that the human cancer genome is
complex, consisting of many somatically acquired genetic and
epigenetic changes [1]. A key challenge faced by the cancer
genetics community is deciphering the role that this complexity
plays in the etiology of human cancer. Unfortunately, we still have
a limited ability to specifically identify those mutations that drive
cancer initiation and progression among the larger number of
passenger mutations found in an individual tumor. A subsequent
goal would then be to determine how individual driver mutations
cooperate to generate and maintain a tumor. Armed with this
knowledge, it is thought that more effective cancer therapies can
be generated to specifically target tumors.
Mouse models of cancer have become a useful tool in modeling
the genetics of human cancer, allowing the investigator to test the
role of mutant forms of specific candidate genes in vivo. Moreover,
insertional mutagenesis models of cancer have shown great promise
not only in the identification of novel candidate cancer genes, but
also in providing insight into how specific combinations of gene
mutations produce cancer [2]. Retroviral, and more recently,
transposon mutagenesis models have been described that model a
wide variety of tumor types in the mouse [2,3]. The great advantage
of these models is that the driver mutations aretagged by proviral or
transposon sequences that facilitate their rapid identification.
Advances in DNA sequencing technology have greatlyfacilitated the
characterization of mouse tumors induced by insertional mutagenesis.
Several independent methods have been produced that utilize a
ligation-mediated PCR approach to amplify proviral or transposon
junction fragments from the tumor genome [4,5]. Incorporation of
barcodes in the PCR allows the products from independent samples to
be mixed and directly sequenced [6,7,8]. This approach has
dramatically increased the amount of data generated from insertional
mutagenesis screens in mouse cancer models.
However, the bioinformatic analysis of data derived from
tumors induced by insertional mutagenesis has also been
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example, tumors that develop in existing mouse models continue
to acquire retroviral or transposon integration events. Although
ongoing insertional mutagenesis increases likely drives tumor
progression in these models, the resulting genetic complexity also
makes it difficult to accurately identify the collection of insertional
mutations that were acquired during the early steps of transfor-
mation. Past analysis has assumed that early integration events
present in the tumor-initiating cell will be present in all tumor cells.
As a consequence, these early events will be clonally expanded to a
greater extent compared to integration events acquired in tumor
subclones. By extension, initiating integration events should be
recurrently PCR-amplified and sequenced. While this is a
reasonable assumption, it is also likely that PCR bias contributes
to the frequency at which specific integration events are amplified
and sequenced. Finally, recent work has shown that many
hundreds of independent insertion events can be identified in an
individual tumor sample [7,8]. Given this complexity, suboptimal
sequence depth is also likely to introduce sampling error and
confound efforts to identify the clonally expanded integration
events associated with early stages of tumor formation.
We have previously developed a variety of mouse models of
cancer in which tumors are induced by Sleeping Beauty
transposon mutagenesis [6,7,8,9,10,11]. Currently, the identifica-
tion of transposon-induced mutations in the tumors from these
models uses pyrosequencing (Roche/454) [6,7,8,9]. This method
generally produces thousands of sequence reads for each sample
analyzed — a significant improvement over standard Sanger
sequencing [10,11]. However, analysis of pyrosequencing data
obtained from repeated sequence runs of the same tumor samples
only identifies a portion of the insertion sites present in each tumor
sample [12]. This suggests that deeper sequencing is required to
capture the complexity of transposon integration sites found in SB-
induced tumors.
Here we describe a new method to identify and analyze
insertional mutations in tumors using Illumina sequencing. Using
two independent sets of transposon-induced tumors, we have
validated this method to determine the sequence depth required to
generate a reproducible integration pattern from each sample to
consistently identify common insertion sites (CISs) in SB-induced
tumors. Our findings suggest that current methods used to
perform this analysis likely lead to the identification of significant
false-positive candidate cancer genes that could largely be
addressed using the approach described here.
Results
Amplification and direct sequencing of transposon
junction sequences
The initial method for identification of transposon insertions
sites made use of the GS FLX sequencing platform (Roche). This
platform was chosen because the longer read length (,100 bp)
was necessary to obtain sufficient sequence information to allow
sample barcoding, verification of transposon structure, and
mapping of the genomic junction sequence. However, the Illumina
sequencing method has recently been improved to achieve longer
sequence reads of 75 bases or greater. We set out to develop a
method to prepare transposon junction amplicons for direct
sequencing on the Illumina platform to take advantage of the
significant increase in sequence depth provided by this approach
(Methods S1).
The initial steps of the ligation-PCR method are similar to those
previously published (Figure S1) [6]. However, the transposon-
specific primer used in the nested PCR step was significantly
redesigned. First, the primer is designed to bind to the sequences at
the ends of the transposon inverted repeats (Figure S1). In
addition, a six-base barcode was used in place of the original ten-
base barcode used previously [6]. These changes reduce the
amount of sequence needed for sample tracking and validation (32
bases), thus increasing the potential read length of the genomic
junction sequence (40–45 bases). Along with these changes, the
59ends of the transposon-specific and adaptor primers are tagged
with the sequences needed to allow each PCR product to bind to
the oligos that coat the surface of the Illumina flow cell. This
modification allows the final PCR products to be directly
sequenced on the Illumina platform, eliminating the need for
additional library preparation steps. Another advantage of this
approach is that it provides the ability for directional sequencing as
a binding site for the standard Illumina genome sequencing primer
is also incorporated into the transposon primer used in the nested
PCR step.
We initially tested this approach using 62 SB-induced tumor
samples using Illumina-based LM-PCR. These samples came from
two previously described models of T-cell lymphoma — Vav-SB
and CD4-SB, with 30 and 32 tumors respectively (Figure S2). All
samples had previously been sequenced on the GS FLX
sequencing platform, thus allowing direct comparison of the two
approaches across many samples. The preparation was done using
two technical replicates where both AluI and NlaIII were used to
generate LM-PCR products from the left inverted repeat (IRL)
and the right inverted repeat (IRR) (Figure S1). Each enzyme and
sample combination was assigned a unique 6-base barcode during
the final nested PCR step. An aliquot of the final LM-PCR
products were analyzed by agarose gel electrophoresis to verify the
quality of the sample (Figure S3). The remaining samples were
then purified to remove unincorporated primers and nucleotides,
and the sample concentration was determined using a Nanodrop
spectrophotometer. Equal amounts of each sample (,250 ng per
sample) were then combined to generate a pooled sample. This
sample was then sequenced in a single lane of a flow cell on a
Illumina Genome Analyzer IIe.
Mapping the reads from the Illumina run posed several
challenges. We have previously described a mapping and
annotation pipeline that was developed to analyze sequence data
produced by pyrosequencing [6]. The sequence reads are mapped
using the BLAT algorithm in the existing pipeline. While this
approach is robust, BLAT cannot map millions of short sequence
reads in a reasonable timeframe. Therefore, we developed a new
analysis pipeline that is optimized for the mapping and annotation
of Illumina sequence data (Figure S4). This pipeline uses the
Bowtie algorithm that was developed to map sequence data from
short read platforms such as Illumina [13].
Our prior work has shown that SB-induced tumors harbor
clonal transposon insertions that drive transformation. These
insertion sites are present in nearly all tumor cells since they are
responsible for initiating transformation. Thus they are clonally
expanded along with the tumor cells. However, it is possible that
each cell within the tumor mass contains a small number of
transposon insertions that are unique to that cell since transpo-
sition is ongoing in all tumor cells. Due to the specificity and
sensitivity of the LM-PCR process, we are able to amplify these
rare transposon insertion events present in only a few cells. Thus
the potential exists to identify hundreds of such background
transposon insertion events in each tumor sample. Consistent with
this expectation, analysis of the Vav-SB and CD4-SB Illumina
sequence data showed that roughly ,95% of mapped integration
sites were represented by 25 or fewer sequence reads. By contrast,
the remaining 5% of transposon integration sites contributed
Illumina-Based Analysis of SB-Induced Tumors
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expansion of specific transposon integration sites is occurring
within the tumor.
Our ultimate goal is to identify candidate cancer genes that are
frequently mutated by transposon insertions within SB-induced
tumors. The current computational methods used to identify these
candidate cancer genes generally work by identifying non-random
clusters of insertion events called CISs. The identification of CISs
uses statistical methods that calculate the expected frequency of
insertion events within a defined genetic interval based on the total
number of insertion events found throughout the genome.
Therefore the inclusion of large numbers of background insertion
events will dilute the insertion profile from tumor cells, thus
decreasing the sensitivity and accuracy of CIS analysis. Therefore,
we investigated methods to identify and remove background
insertion events prior to CIS analysis.
Initially, we examined the distribution of reads across the
integration sites identified in each sample and found that the
distribution of reads differed between individual samples. In
addition, the distribution of reads varied between the results
obtained using different restriction enzymes (i.e. AluIo rNlaIII) for
a single sample. Nevertheless, Illumina sequencing identified
significantly more insertion events when compared directly to 454
sequencing results obtained from identical samples (Figure S5).
Because of the varied read distributions, we developed three
different methods to identify and remove background insertion
events. Recently published ChIP-Seq algorithms use a negative
binomial distribution to identify background sequences that do
show enrichment [14]. Since SB data sets have a similar
distribution to ChIP-Seq experiments, a negative binomial
distribution (NB) was fit to all integration sites found in each
barcoded sample represented by three or fewer reads. This process
is then used to identify the set of integrations that are more
prevalent than expected based upon the NB-estimated background
(Fig. 1). These sites are defined as clonally expanded events, and all
other sites are discarded.
While the NB procedure provides a reliable method to identify
clonal sites, the read distribution in many samples does not
adequately fit a negative binomial distribution. This is particularly
true at higher read depths (Fig. 1). In these situations, the NB
method fails to exclude many background insertion events.
Therefore, two alternative approaches can be applied. The first
method requires all clonal insertion events have a read count that
is at least 1% of the most abundant insertion site. The final method
requires that all clonal insertion sites be represented by a
minimum of 0.1% of the total reads for the sample. As shown in
Figure 1, the stringencies of these three methods vary depending
on the read distribution and depth. Therefore, the analysis
pipeline uses a more dynamic filtering process by calculating the
read cutoff for each sample using all three methods and then
applying the highest cutoff value. This dynamic cutoff method
eliminates the greatest number of background insertion events,
thus providing the most stringent definition of clonal transposon
insertion events (Table S2).
Determining the accuracy of Illumina-based LM-PCR
The lack of consistency seen in the 454-based LM-PCR method
could be caused by variations in sample preparation or sampling
error due to insufficient read depth. To test the former, we
compared the results obtained in the technical replicates (Fig. 2).
Figure 1. Dynamic filtering to remove background transposon insertion events. (A) Read distributions from two independent tumor
samples are shown along with the calculated cutoff points using three independent methods: negative binomial (NB), 1% of the top (i.e. most
abundant) site and 0.1% of total reads (B) An experiment to simulate a variety of sequence read depths shows that the cutoff method used by the
analysis pipeline is influenced by read depth.
doi:10.1371/journal.pone.0024668.g001
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samples as described previously. Next, the clonal transposon
insertion sites were rank ordered based on the frequency at which
each site was sequenced. The ranks from each technical replicate
across all samples were compared, and a significant positive
correlation (r
2=0.87) was observed (Fig. 2B). Next, we calculated
the percentage of total reads found for each clonal insertion site
and compared these values for each site between the two
replicates. Again, a strong positive correlation (r
2=0.9) was
observed between the technical replicates (Fig. 2C). These results
suggest that variation in sample preparation does not contribute
significantly to the read distribution.
Determining optimal sequence depth
We next examined how varying read depth affects the
identification of clonal transposon insertion sites to determine
the minimum sequence depth required to obtain a consistent
result. This was accomplished by random sampling of mapped
reads to simulated a variety of read depths ranging from 1,000 to
150,000 reads per sample. The average number of clonal sites
found in all tumors for both the Vav-SB and CD4-SB models was
determined based on the results from 20 independent simulations
across 19 different read depths (Fig. 3). The clonal insertion sites
were identified for each sample in all iterations as described above.
Not surprisingly, the average number of clonal insertion sites
increases significantly with greater read depths. The results
indicate that simulated read depths that approximate 454
sequencing (Fig. 3, gray boxes) identify only ,65–75% of clonal
sites identified at greater read depths. Interestingly, the simulation
results for both tumor models suggest that modest increases in read
depth initially introduce background insertion sites that are
eliminated with the addition of more sequence data (Fig. 3A).
While the average number of clonal sites stabilizes beyond a
read depth of 100,000, the composition of the data sets may
fluctuate significantly. We next calculated the percentage of sites
that were seen in 80, 90, or 100% of the iterations (Fig. 3B). Again,
at read depths that approximate 454 sequencing, roughly 40–50%
of the clonal sites were found in 90% of the iterations. The
consistency improves steadily as sequence depth increases, as
expected. Taken together, the simulation experiments indicate
that an average of 100,000 mapped reads per sample are required
to reproducibly discover clonal insertion events.
Determining the impact of PCR-bias on LM-PCR results
It has been well established that PCR can introduce significant
bias in the amplification of genomic DNA fragments. A number of
parameters have been shown to influence the extent to which any
fragment will be amplified including fragment length, GC content
and secondary structure [15,16]. Because of this concern, our
Illumina-based LM-PCR approach identifies transposon insertion
events using four distinct approaches using two different restriction
enzymes in an effort to combat the effects of PCR bias. As the goal
Figure 2. Illumina-based LM-PCR analysis consistently identifies transposon insertions in SB-induced tumors. A total of 62 T-cell
lymphomas induced by SB mutagenesis using a ligation-mediated PCR approach were analyzed. Two technical replicates were performed to assess
the consistency of the results (A). The results of the technical replicates were compared to assess the reproducibility of the approach. Both the rank
(B) and abundance (C) of insertion sites showed a strong positive correlation between the replicate runs.
doi:10.1371/journal.pone.0024668.g002
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complex samples, we examined how extensively PCR bias affects
the identification of transposon insertion sites in SB-induced
tumors using the Illumina-based LM-PCR method.
Over 6,000 clonal transposon insertion sites were identified in
62 samples, as previously described (Table S1). These sites were
identified, in part, by assuming that the read number for each
individual junction fragment is correlated to the abundance of the
specific insertion event that produced it. However, the read
number could also be influenced by PCR bias, the most likely
source being fragment length. Therefore, we calculated the size of
the AluI and NlaIII restriction fragments that each clonal insertion
site produced based on the mouse reference genome sequence.
Next, we determined the percentage of clonal junction fragments
that were identified at each length ranging from 20 to 500 bases.
These values were chosen because they represent the technical
limits to our analysis pipeline.
As shown in Figure S6, there is some preference for
amplification of smaller junction fragments, although the effects
of PCR bias do not appear to be dramatic. Nevertheless, there is
preference for amplification of PCR fragments that are less than
250 bases in length (Figure S6). We then determined the
percentage of genomic TA sites (i.e. SB target sites) in which all
four approaches fail to produce a junction fragment less than 250
bases in length. This analysis indicates that ,3% of TA sites would
not compete well for amplification using our Illumina-based LM-
PCR approach — a relatively modest number of sites. Finally, we
sought to determine the extent to which the identification of clonal
transposon insertion events is affected by PCR bias. This revealed
that ,70% of clonal insertion events were identified as clonal in at
least 3 of the 4 libraries generated for each sample (Figure S6).
This result suggests that while PCR bias does influence the read
number for each insertion site, PCR bias does not greatly impact
the identification of clonal insertion sites in tumor samples.
However, additional experiments are required to determine if this
method provides quantitative information beyond the identifica-
tion of clonal insertion sites.
Identification of driver mutations
We have shown that the Illumina-based LM-PCR method
significantly outperforms previous methods in its ability to
reproducibly identify clonal transposon insertion events within
SB-induced tumors. Next, we sought to determine how the
Illumina-based LM-PCR method affects the identification of CISs,
the functional equivalent of driver mutations in SB-induced tumor
models. Previous studies have used one of two methods to identify
CISs, Gaussian Kernel Convolution (GKC) or a Monte Carlo
(MC) simulation [6,7,8,17]. Both methods assume that back-
ground mutations will happen at random throughout the genome
and that causative mutations will cluster in regions near or within
cancer genes. These regions are statistically defined as those that
have a higher mutation rate than expected by chance. A strength
of the GKC and MC approaches is that they are relatively
unbiased in the identification of CISs. Neither method considers
annotated functional elements within the genome, and thus they
are well suited to identify novel or poorly characterized genes.
However, GKC and MC can also identify CISs that are too small
or large to be biologically meaningful, and thus the gene target of
some CIS regions is difficult to identify.
Given the limitations of the GKC and MC methods, we
developed a novel computational method to identify CIS regions
in SB-induced tumors. In contrast to the previous methods, this
Figure 3. Determining optimal read depth in SB-induced tumors. (A) An experiment was performed to simulate various read depths in 30
Vav-SB (left) and 32 CD4-SB (right) tumors. The average number of clonal transposon insertion sites was determined from 20 independent iterations
of each read depth simulation. (B) The consistency of transposon insertion site identification varied with sequence depth. For example, only 10% of
transposon insertion sites were identified in 100% simulations at a simulated read depth of 1,000.
doi:10.1371/journal.pone.0024668.g003
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genome to identify genes that are mutated at a rate higher than
expected by chance. We refer to this method as gene-centric
common insertion site (gCIS) analysis. The gCIS method
calculates the observed and expected number of insertion events
within each RefSeq gene. The expected number of insertion
events is based on the number of tumors analyzed, the number of
insertion events within each tumor and the number of SB target
sites within each RefSeq transcription unit, including 10 kilobases
of promoter sequence. These values are used to perform a Chi-
square test, yielding a p-value for each RefSeq gene. A Bonferroni
correction is applied to correct for multiple hypothesis testing. Any
remaining RefSeq genes that were not mutated in at least three
independent tumors are also eliminated.
We next determined how each of the three methods performed
in analyzing sequence data generated using the Illumina-based
LM-PCR method (Fig. 4). This analysis identified a total 32 and
97 CISs in Vav-SB and CD4-SB tumors, respectively. GKC and
MC identified similar gene sets in both models. This outcome was
expected given the similarity in these computational methods. By
contrast, the gCIS method not only identified ,90% CISs found
by GKC and MC, but 1.5 to 2-fold more CISs unique to this
approach. The unique CIS genes found by the gCIS approach
show a similar degree of overlap with known human cancer genes
found in the COSMIC [18] and Cancer Gene Census [19]
databases (Fig. 4). This suggests that the gCIS method performs
well and is capable of identifying novel CISs that are missed by
prior methods (Figure S7). While the GKC and MC methods do
not identify many unique CIS regions, the CIS regions called by
these methods often contain more insertion events than the
corresponding region identified by gCIS analysis. For example, of
the 59 genes identified by both MC and gCIS (Fig. 4), MC
identified more insertion events within the CIS region than did
gCIS in over 30% of cases. While this difference did not affect the
identification of these genes, the relative mutation frequencies as
determined by each method frequently varied. Thus, there is
benefit from analyzing data sets with multiple methods (e.g. MC
and gCIS).
Finally, we compared the results of CIS analysis that were
obtained using either 454 or Illumina sequencing of the same
tumor cohort (Fig. 4C,D). The results show that Illumina
sequencing identifies ,2-fold more driver mutations in both
lymphoma models. Not surprisingly, 454 sequencing identified a
population of CIS genes that were not identified by Illumina
sequencing. However, the majority of these genes (21/22) were
identified by Illumina sequencing but not identified as a driver
mutation using MC or gCIS methods (Table S3).
Accuracy of CIS identification
Here we have shown that the reproducible identification of
transposon insertion sites requires ,20-fold more sequence data
than is currently used to characterize SB-induced tumors (Fig. 3).
Figure 4. Comparison of three independent methods to identify CISs within SB-induced tumors. We compared the performance of
Monte Carlo simulation (MC), Gaussian Kernel Convolution (GKC) and gene-centric common insertion site analysis (gCIS) in identifying candidate
cancer genes in both Vav-SB (A) and CD4-SB (B) tumors. In addition, the number in parentheses indicates the number of total genes in each region
that have evidence as human cancer genes in either the COSMIC or CGC databases. In addition, we compared the results of MC and gCIS analysis
using data generated by 454 or Illumina sequencing of the same tumor samples in both Vav-SB (C) and CD4-SB (D) lymphoma models.
doi:10.1371/journal.pone.0024668.g004
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the accuracy of CIS identification. To test this hypothesis, we
again performed simulations in which random sequences were
selected to mimic various read depths. Twenty iterations were
performed for each sequence depth, and gCIS analysis was
performed on the data set generated for each iteration. Next, we
calculated the total and average number of genes that were called
at each sequence depth (Fig. 5A). Consistent with the results of the
previous simulation experiment, the gCIS results varied widely at
intermediate sequence depths. However, as sequence depth
increased, the gCIS results became more consistent.
This result suggested that the accuracy of the gCIS method at low
to intermediate sequence depths is likely lower than anticipated. We
next calculated the accuracy of gCIS identification using the
simulation results. The prior simulation results indicated that
sequence depths .100,000 reads per sample provide consistent
gCIS results (Fig. 5A). Therefore, we defined the gCIS gene set
identified using all sequence data as the reference data set. The
average sensitivity and accuracy of gCIS analysis was then
determined by comparing the results obtained for each iteration
and sequence depth to the reference data set (Fig. 5B). As predicted,
the sensitivity of gCIS detection is relatively poor at low sequence
depths. This was confirmed by comparing the results of the
simulation to the actual data obtained using 454 sequencing (Fig. 5).
For the most part, the 454 results were similar to the predicted
outcome based on the sequence depth simulations, although the
actual 454 data consistently performed worse than predicted.
In general, the gCIS analysis performed much better across a
range of sequence depths in Vav-SB tumors. We have previously
shown that the CD4-SB tumors show greater genetic complexity
than Vav-SB tumors, harboring more mutations per sample that
affect a larger number of genes [20]. As a consequence, the
accuracy and sensitivity of gCIS identification in CD4-SB tumors
are more significantly affected by inadequate sequence coverage.
The distinction between the Vav-SB and CD4-SB tumor models is
clearer when the genomic distributions of driver mutations are
compared (Fig. 6). Not surprisingly, the majority of CIS genes in
the Vav-SB model can be identified at low to moderate sequence
depths. By contrast, the identification of many CIS genes in the
CD4-SB model requires additional sequence data. This result
indicates that tumor complexity in SB-induced models of cancer
will determine the needed sequence depth to consistently identify
CIS genes. It is also important to note that increased sequence
depths are required to identify and eliminate false-positive CIS
genes regardless of tumor complexity. For example, the majority of
CIS regions identified at a read depth of 5,000 reads per sample
are eliminated with the addition of more sequence data (Fig. 6,
white bars). In this regard, the Illumina-based LM-PCR method
would likely reduce the false-discovery rate of CIS identification,
assuming sufficient sequence coverage is obtained for each sample.
Discussion
As with the identification of somatic mutation in human tumors,
the analysis of transposon-induced mutations in SB models of
cancer relies on the sensitivity to detect mutations within
heterogeneous tumor cell populations. The Illumina-based LM-
PCR method we describe here shows a marked improvement in
Figure 5. Determining the affect of sequence depth on the accuracy of CIS identification. Read depth simulations were performed as
previously described. However, gCIS analysis was performed on each of 20 iterations at all simulated read depths. In addition, the values generated
from analysis of the actual 454 data obtained for the same tumor samples are shown. (A) The total number of gCIS genes identified in at least one of
the 20 iterations is indicated along with the average number of gCIS genes at each simulated sequence depth. (B) The gCIS results obtained by
analyzing all sequence data in both tumor models were used as reference data sets. The accuracy (% of genes found in reference set) and sensitivity
(% of genes in reference set that were detected) were determined. For example, only 41% of the reference gCIS genes in the Vav-SB model were
found at a depth of 1,000 reads per sample (i.e. 41% sensitivity). However, 90% of gCIS genes identified at this read depth were found in the reference
data set (i.e. 90% accuracy).
doi:10.1371/journal.pone.0024668.g005
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fold (Table S1). This increase in sequence coverage led to a 15-fold
increase in the average number of mapped transposon insertion
sites per sample.
The sheer number of insertion sites identified per sample
(.15,000) provides clear evidence that the Illumina-based LM-
PCR is capable of identifying rare transposon insertion events
likely present in a small percentage of cells. These rare insertion
events significantly outnumber the clonally expanded insertion
events that are also present in each tumor sample (Fig. 1). Their
inclusion in the data set confounds efforts to identify CIS genes in
these tumors cohorts. Therefore, we devised three independent
methods to identify and remove such background sites prior to
CIS analysis. Our analysis shows that not only that these
background insertion sites must be removed, but that multiple
methods are required for this process (Fig. 1B). For example, the
CIS genes identified using the dynamic cutoff method showed the
greatest overlap with genes implicated in human cancer (Table
S2).
The need for such a dynamic cutoff method is likely caused by
heterogeneity within SB-induced tumors. Transposon copy
number has been shown to affect tumor latency and the
complexity of transposon insertion sites [6,9]. The Vav-SB and
CD4-SB tumors were generated using high copy transposon donor
strains [11]. Therefore, these tumors typically harbor a greater
number of clonal transposon insertion events when compared to
similar tumors generated using low copy transposon donor strains.
With this knowledge, our goal was to develop an analysis pipeline
that is more dynamic, allowing it to process data derived from a
variety of transposon strains without further optimization. Thus
the dynamic cutoff method was employed.
Another benefit of increased sequence depth is that it provided
the opportunity to simulate the effects of varying sequence
coverage on all aspects of insertion site analysis. Prior publications
have relied on 454 sequencing to identify transposon-induced
mutations in SB models of cancer. We have shown that ,20-fold
increase in sequence depth over what is achieved with 454 is
required to eliminate sampling error and consistently identify
clonal transposon insertion events. Increased sequence coverage
also provided more consistent results in the identification of CIS
genes.
The Illumina-based LM-PCR approach we describe here is
clearly superior to the prior 454-based method that we and others
have used to characterize SB-induced tumors. However, we have
also shown that the results of this approach are influenced by PCR
bias. However, the effects of PCR bias are mostly offset by
employing four different approaches to identify insertion sites. It
should be noted that it is not possible to infer any additional
quantitative information from the Illumina-based sequencing
method, aside from the identification of clonal transposon
insertion sites, given the persistent PCR bias observed. Likely this
bias is caused by the continued use of restriction enzymes to
Figure 6. The affect of varying read depth on the genomic distribution of CIS genes. The genomic position of each CIS gene is indicated as
a vertical bar. The color of the bar indicates the minimum number of reads per sample required to consistently identify the CIS gene at the indicated
position. The height of the bar indicates the mutation frequency within the each tumor model as determined by analysis of all sequence data. A large
number of false-positive CISs were identified in one or more iterations of the simulation to approximate a read depth of 5,000 (white bars).
doi:10.1371/journal.pone.0024668.g006
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restrictive LAM-PCR [21] or the use of physical shearing to
fragment the genome could eliminate the PCR bias we observed.
Regardless, additional work is required to establish a truly
quantitative approach to identify transposon insertion sites in
SB-induced tumor samples. This type of quantitative method will
likely be needed to more specifically identify transposon insertion
sites that have been clonally expanded in tumor cell populations.
In addition to the Illumina-based LM-PCR method, we also
describe a novel computational method to identify CIS genes in
SB-induced tumors. We show that the gene-centric CIS (gCIS)
method is capable of identifying a novel set of genes that are
missed by established methods (e.g. MC, GKC). A subset of the
gCIS-specific genes are also mutated in human cancer, suggesting
that this approach will be useful in extracting additional genetic
information from SB-induced tumors. Another advantage of the
gCIS method is that it provides an individual assessment of all
RefSeq genes in the mouse genome, while the MC and GKC
methods are less specific in the identification of driver mutations.
As a consequence, the gCIS method provides an output that will
facilitate comparative oncogenomic approaches using genetic data
derived from human tumors. Thus the gCIS method complements
the exiting computation approaches currently in use.
Rapid improvements in DNA sequencing technology have now
made tumor genome sequencing a reality. However, early efforts
in this area suggest that while sequencing the human cancer
genome is achievable, our ability to understand the biological
significance of each somatically acquired mutation within an
individual’s tumor is somewhat limited. Largely this is due to our
inability to accurately identify driver mutations within the larger
field of passenger mutations that coexist within each tumor. Thus,
additional experimental evidence will be needed to assess the
potential of each candidate driver mutation that is identified by the
tumor genome sequencing.
Genetically engineered mouse models have been used to study a
variety of cancer-relevant phenotypes. In addition, mouse models
of cancer have been exploited to identify common genetic
mechanisms that drive both mouse and human cellular transfor-
mation. More recently, in vivo insertional mutagenesis has been
used to generate mouse models of cancer in which the
identification of candidate cancer genes is dramatically accelerated
[6,7,12,22,23]. Recent work has demonstrated the advantage of
using insertional mutagenesis to study a variety of cancer-relevant
phenotypes such as metastasis and acquired drug resistance in
mouse models of cancer [7,24]. The method we describe here will
improve the quality of data and provide greater confidence in the
identification of candidate cancer genes in these SB models of
cancer. Ultimately, our work will improve the ability to use SB
models to perform comparative oncogenomics to assist in
deciphering the human cancer genome.
Methods
Tumor cohort
The Vav-SB and CD4-SB mouse models are described
previously [20]. All tumors used in this study were collected from
mice using procedures approved and monitored by the Institu-
tional Animal Care and Use Committee at the University of Iowa.
Read Analysis
Reads were analyzed using the Integration Analysis System
(IAS). This pipeline was run independently on each lane. The
inputs to the pipeline were a FASTA file containing all the
sequencing reads and a barcode file that per barcode contains: the
barcode sequence, the name for the tumor, IRL or IRR (to
indicate which from which inverted repeat the sequence is
derived), and the expected flanking sequences. Using the barcode,
each sequence was placed into a tumor specific file. Crossmatch (P.
Green, unpublished) identifies the presence and location of the
flanking sequences. This information is used to trim the flanking
sequences from the genomic segment. All sequences were then
verified to begin with a ‘‘TA’’ dinucleotide. The genomic
sequences were then aligned to the mouse genome reference
assembly (NCBI37/mm9) using Bowtie [13]. The parameters used
were ‘‘–best -f -k2 –p7 –v3’’ which gives the top two hits and only
allows 3 mismatches in the sequence. The Bowtie output was then
filtered using the following criteria: the best match had to be at
least 90% identical, including a perfect match to the ‘‘TA’’ at the
start of the alignment, be at least 5% better than the second best
match, and have 2 or less mismatches. Using the refFLat table
from the UCSC genome databases [25], we retrieved the gene-
centric data with which to annotate the integrations. The
annotation file included the following information: [tumor ID],
[gene name], [gene region hit (i.e. intron, exon)], [predicted affect
of transposon insertion on gene expression], [distance from gene],
[chromosome], [address], [percent of reads derived from the
insertion site], and [transposon orientation relative the gene].
After each annotation file is generated, all transposon insertion
events that map to the same chromosome as the transposon donor
transgene were removed. This was done to eliminate any bias
caused by local hopping of SB transposons. Next, the clonality
cutoff was calculated for each annotation file. The clonal insertion
sites identified in each of the four LM-PCR libraries generated for
each sample (Figure S1) were then combined to generate a non-
redundant list of insertion sites identified in each sample. In cases
where an insertion site was identified in multiple libraries, the
largest value representing the percent of reads derived from the
insertion site is used.
Identifying clonal insertion sites
Three methods were used to identify clonal insertion events
within each tumor sample. All three methods are preformed
independently on the reads obtained for each barcode, and the
maximum cutoff value is applied. The negative binomial models
the background distribution. The background is estimated by
fitting a negative binomial distribution to the distribution of sites
with 1–3 reads. These sites were selected to model the background
because we are confident that these sites are not clonally
expanded. The number of reads was zero shifted to better
approximate the negative binomial. The dnbinom module in R
was then used to generate the negative binomial distribution. The
best fit to the negative binomial distribution was determined by
minimizing the least squared error across all iterations of the size
and probability parameters in steps of 0.01 and 0.001, respectively.
The NB threshold was calculated as the read depth at which 95%
of the integration sites are under the curve. Thus only 5% of the
background distribution is expected to contribute to the set of
clonal sites. A second cutoff value was calculated by taking 1% of
the read number observed for the most abundant site. The third
cutoff value was defined as the value representing 0.1% of the total
reads for the barcode.
Identifying Causative Genes
The Monte Carlo simulation and Gaussian Kernel Convolution
were performed essentially as previously published [6,17]. Gene-
centric CISs (gCIS) were defined based upon the number of TA
dinucleotides within the transcribed region for each gene in the
RefSeq collection. The gene-associated region was defined as the
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A chi-squared test statistic was calculated based upon the number
of TAs within each gene-associated region and the number of
integrations within the gene. This test statistic was used to
determine the p-value, with a single degree of freedom. A tab-
delimited file was generated detailing the results for each RefSeq
gene including the gCIS p-value, number of tumors in which
integrations were found, and a list of the tumor IDs in which
integrations were observed. Using the Bonferroni method, a
statistical threshold of p=2.6361026 was used to correct for
multiple hypothesis testing. A final condition applied to all
methods was a requirement for each CIS to harbor a minimum
of three independent tumors with insertions in the gene.
Simulation of read depth
To simulate read depth, we randomly sampled with replace-
ment mapped reads from a pooled set. This set contained the map
location of the read and corresponding tumor ID from which it
was identified. Twenty iterations of each read depth were
generated, and the average number of clonal insertion sites was
calculated for each tumor model. The consistency of insertion site
identification was calculated by calculating the percentage of
insertion sites that were identified in 80, 90 or 100% of the
iterations for each read depth. In addition, gCIS analysis was
performed on each of the twenty iterations at each read depth.
These results were then compared the reference gCIS data set (i.e.
true positives) obtained by analyzing all sequence data. Thus for
each simulated read depth, gCIS accuracy is the percentage of
gCIS genes found at each read depth that are also present in the
reference data set. The gCIS sensitivity is the percentage of gCIS
genes in the reference data set that is found at each simulated read
depth.
Comparison to human cancer genes
A comparative oncogenomics approach was used to assess the
extent to which CIS analysis identifies genes implicated in human
cancer. This was done by comparing individual CIS genes are
mutated in the COSMIC and Cancer Gene Census databases
[18,19]. While the Cancer Gene Census contains only validated
cancer genes, the COSMIC database contains data on more than
19,000 genes. Somatic mutations have been identified in only a
subset of these genes. We generated a list of COSMIC genes that
have a mutation frequency of at least 5% with a minimum of 5
independent somatic mutations. Ultimately, we identified 807
genes that have supporting evidence of somatic mutation in
human tumors and clear mouse orthologs.
Supporting Information
Figure S1 Overview of ligation-mediated PCR strategy
to amplify transposon-genomic junctions from SB-
induced tumors. Each tumor DNA is digested with either AluI
or NlaIII restriction enzyme. These enzymes create junction
fragments on both ends of each integrated transposon. Double-
stranded adaptors are then ligated to the ends of all genomic DNA
fragments. The adaptor is modified to such that the adaptor
primer used in the primary PCR reaction cannot hybridize until
the transposon-specific primer first generates the complementary
strand. Nested PCR is then performed using a primers modified to
include the sequence tags required for direct sequencing on the
Illumina platform.
(PDF)
Figure S2 (A) Overview of Sleeping Beauty (SB) models
of cancer. (B) We used a Cre-inducible SB transposon
mutagenesis system to generate two distinct models of T-cell
lymphoma in which mutagenesis was initiated in either hemato-
poietic stem cells (Vav-SB) or in nearly differentiated thymocytes
(CD4-SB). (C) Tumors within Vav-SB and CD4-SB mice develop
with different latencies and are driven by distinct mutations. The
major findings of this work are described elsewhere [20].
(PDF)
Figure S3 An aliquot of the secondary LM-PCR product
(25 ml of a 100 ml reaction) is analyzed by agarose gel
electrophoresis to verify the quality of the sample. The
above example is a typical result for the LM-PCR
process. Products typically appear as a low molecular weight
smear, although some samples have more abundant junction
products that appear as bands. Failed reactions may have only a
primer dimer band of ,100 bp. The LM-PCR process is repeated
on these samples until a similar result is obtained. [DNA marker is
the 1 kb+ ladder (Invitrogen). Indicated bands are base pair
values.]
(PDF)
Figure S4 Overview of sequence analysis pipeline. The
raw Illumina sequence file (FASTQ formatted) and the barcode
file containing the metadata for each tumor sample are the inputs
for the analysis pipeline. The order and a brief description for each
stepwise process is shown.
(PDF)
Figure S5 The read distribution is shown for two
different samples that were analyzed by both Illumina
(A) and 454 (B) LM-PCR. The increased sequence depth in the
Illumina method apparently improves the signal to noise ratio and
identifies more clonal insertion sites than 454 sequencing.
(PDF)
Figure S6 Effects of PCR bias on the results of Illumina-
based LM-PCR. The average restriction fragment sizes
generated by clonal transposon insertions in CD4-SB (A) or
Vav-SB tumors (B) is shown. This clearly shows preferential
amplification of smaller junction fragments as they are more
abundant than expected given the size distribution in the genome
(shown in red). However, this trend appears to be similar in
junction fragments that were identified as clonal (white circles) or
subclonal (gray circles) transposon insertion sites. (C) Based on the
range of product sizes that are preferentially amplified (A–B, gray
box), we determined the percentage of genomic TA sites that
would be subject to negative PCR bias in all four libraries. While
PCR bias is evident, it does not appear to dramatically affect the
identification of clonal transposon insertion sites. (D) The majority
of clonal sites were identified as clonal in at least three of the four
junction libraries generated for each tumor.
(PDF)
Figure S7 The gene-centric common insertion site
(gCIS) approach was designed to identify genes that
suffer transposon-induced mutations at a rate higher
than expected given the number of tumors, number of
insertion sites per tumor and the number SB target sites
in each gene. This method is capable of identifying driver
mutations that are not identified by existing methods (MC, GKC)
that rely on transposon clustering to identify common insertion
sites. As a consequence, diffuse clusters of insertion events in some
genes are missed by these methods. By contrast, the gCIS method
can identify these genes as significant driver mutations. Shown
here are three such examples. In each case, MC failed to identify
the gene as a driver mutations while gCIS identified it as a
candidate cancer gene. The general structure is shown for each
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ing arrows indicating the position of transposon insertions (green
arrow=forward transposon orientation, red arrow=reverse
transposon orientation).
(PDF)
Table S1 Summary analysis using 454 and Illumina-
based LM-PCR.
(PDF)
Table S2 Comparison of cutoff methods in the identi-
fication of CIS and gCIS genes.
(PDF)
Table S3 Comparison of CIS genes identified by 454
and Illumina sequencing in SB-induced lymphomas.
(PDF)
Methods S1 Detailed Illumina-based LM-PCR protocol.
(PDF)
Author Contributions
Conceived and designed the experiments: AJD BTB TES JH. Performed
the experiments: KEBV KN BTB. Analyzed the data: BTB AJD. Wrote
the paper: AJD BTB.
References
1. Mardis ER, Wilson RK (2009) Cancer genome sequencing: a review. Hum Mol
Genet 18: R163–168.
2. Kool J, Berns A (2009) High-throughput insertional mutagenesis screens in mice
to identify oncogenic networks. Nat Rev Cancer 9: 389–399.
3. Dupuy AJ (2010) Transposon-based screens for cancer gene discovery in mouse
models. Semin Cancer Biol.
4. Largaespada DA, Collier LS (2008) Transposon-mediated mutagenesis in
somatic cells: identification of transposon-genomic DNA junctions. Methods
Mol Biol 435: 95–108.
5. Uren AG, Kool J, Matentzoglu K, de Ridder J, Mattison J, et al. (2008) Large-
scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes
and their collaborative networks. Cell 133: 727–741.
6. Dupuy AJ, Rogers LM, Kim J, Nannapaneni K, Starr TK, et al. (2009) A
modified sleeping beauty transposon system that can be used to model a wide
variety of human cancers in mice. Cancer Res 69: 8150–8156.
7. Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, et al. (2009) A
conditional transposon-based insertional mutagenesis screen for genes associated
with mouse hepatocellular carcinoma. Nat Biotechnol 27: 264–274.
8. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, et al. (2009) A
transposon-based genetic screen in mice identifies genes altered in colorectal
cancer. Science 323: 1747–1750.
9. Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, et al. (2009) Whole-
body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and
rare high-grade glioma without associated embryonic lethality. Cancer Res 69:
8429–8437.
10. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA (2005)
Cancer gene discovery in solid tumours using transposon-based somatic
mutagenesis in the mouse. Nature 436: 272–276.
11. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA (2005)
Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty
transposon system. Nature 436: 221–226.
12. Starr TK, Scott PM, Marsh BM, Zhao L, Than BL, et al. (2011) A Sleeping
Beauty transposon-mediated screen identifies murine susceptibility genes for
adenomatous polyposis coli (Apc)-dependent intestinal tumorigenesis. Proceed-
ings of the National Academy of Sciences of the United States of America 108:
5765–5770.
13. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome. Genome
biology 10: R25.
14. Ji H, Jiang H, Ma W, Johnson DS, Myers RM, et al. (2008) An integrated
software system for analyzing ChIP-chip and ChIP-seq data. Nature
biotechnology 26: 1293–1300.
15. Harkey MA, Kaul R, Jacobs MA, Kurre P, Bovee D, et al. (2007) Multiarm
high-throughput integration site detection: limitations of LAM-PCR technology
and optimization for clonal analysis. Stem cells and development 16: 381–392.
16. Schmidt M, Schwarzwaelder K, Bartholomae C, Zaoui K, Ball C, et al. (2007)
High-resolution insertion-site analysis by linear amplification-mediated PCR
(LAM-PCR). Nature methods 4: 1051–1057.
17. de Ridder J, Uren A, Kool J, Reinders M, Wessels L (2006) Detecting statistically
significant common insertion sites in retroviral insertional mutagenesis screens.
PLoS computational biology 2: e166.
18. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, et al. (2011) COSMIC:
mining complete cancer genomes in the Catalogue of Somatic Mutations in
Cancer. Nucleic acids research 39: D945–950.
19. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of
human cancer genes. Nature reviews Cancer 4: 177–183.
20. Berquam-Vrieze KE, Nannanpaneni K, Brett BT, Holmfeldt L, Ma J, et al.
(2011) Cell of origin strongly influences genetic selection in mouse models of T-
ALL. Blood (in press).
21. Paruzynski A, Arens A, Gabriel R, Bartholomae CC, Scholz S, et al. (2010)
Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-
generation sequencing. Nature protocols 5: 1379–1395.
22. Rad R, Rad L, Wang W, Cadinanos J, Vassiliou G, et al. (2010) PiggyBac
Transposon Mutagenesis: A Tool for Cancer Gene Discovery in Mice. Science
330: 1104–1107.
23. Vassiliou GS, Cooper JL, Rad R, Li J, Rice S, et al. (2011) Mutant
nucleophosmin and cooperating pathways drive leukemia initiation and
progression in mice. Nature genetics.
24. Lauchle JO, Kim D, Le DT, Akagi K, Crone M, et al. (2009) Response and
resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature
461: 411–414.
25. Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D, et al. (2011) The
UCSC Genome Browser database: update 2011. Nucleic acids research 39:
D876–882.
Illumina-Based Analysis of SB-Induced Tumors
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24668